



(51) International Patent Classification:

A61K 38/16 (2006.01) A61P 19/02 (2006.01)
A61K 38/39 (2006.01) A61P 37/06 (2006.01)

(21) International Application Number:

PCT/US2022/077182

(22) International Filing Date:

28 September 2022 (28.09.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/249,553 28 September 2021 (28.09.2021) US
63/375,282 12 September 2022 (12.09.2022) US

(71) Applicant: **VIELA BIO, INC.** [US/US]; 1 Horizon Way,
Deerfield, Illinois 60015 (US).

(72) Inventors: **ALEVIZOS, Ilias**; c/o Viela Bio, Inc., 1 Horizon Way, Deerfield, Illinois 60015 (US). **ILLEI, Gabor**; c/o Viela Bio, Inc., 1 Horizon Way, Deerfield, Illinois 60015 (US). **REES, William**; c/o Viela Bio, Inc., 1 Horizon Way, Deerfield, Illinois 60015 (US). **DRAPPA, Jorn**; c/o Viela Bio, Inc., 1 Horizon Way, Deerfield, Illinois 60015 (US).

WANG, Liangwei; c/o Viela Bio, Inc., 1 Horizon Way, Deerfield, Illinois 60015 (US).

(74) Agent: **BROWN, Fraser** et al.; COOLEY LLP, 1299 Pennsylvania Avenue NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: CD40L-SPECIFIC TN3-DERIVED SCAFFOLDS FOR THE TREATMENT AND PREVENTION OF SJOGREN'S SYNDROME




FIG. 1

(57) Abstract: Provided are compositions and methods comprising a CD40L-specific Tn3 scaffold. Also provided are methods of utilizing the same for the prevention and treatment of Sjögren's Syndrome.

[Continued on next page]

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*